RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events Biomarkers and measures of neurodevelopmental function from patients in Cohorts ...
Expanded Access and Right To Try Requests: The Community Oncologist's Experience We hypothesized that because of availability of ICIs, systemic therapy use in the last 30 days of life (DOL) would have ...
Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy, named WFX-001, being developed for the treatment of Fabry disease.
Morgana Freeman, MD: The use of hedgehog inhibitors really relies on our understanding of how basal cell carcinoma [BCC] uniquely grows. Basal cell carcinoma relies on something called the smoothened ...
Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...
Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results